A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1

Active, not recruiting

• Conditions: KRAS p.G12C Mutant Advanced Solid Tumors
• Interventions: Drug: sotorasib; Drug: Anti PD-1/L1; Drug: Midazolam

• Registration Number: NCT03600883
• Lead Sponsor: Amgen

Brief Summary

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-06-26
• Study First Submitted QC: 2018-07-17
• Study First Posted: 2018-07-26
• Study Start: 2018-08-27
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-05
• Last Update Posted: 2025-02-07
• Primary Completion: 2028-05-30
• Study Completion: 2028-05-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 713

Inclusion Criteria

• Men or women greater than or equal to 18 years old.
• Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.

Exclusion Criteria

• Active brain metastases from non-brain tumors.
• Myocardial infarction within 6 months of study day 1.
• Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Phase 1 Dose Exploration Part 1 monotherapy	sotorasib	Cohorts with food effect and alternative dosing regimens Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort
Phase 1 Dose Expansion Part 2 monotherapy	sotorasib	Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently
Phase 1 combination arm with sotorasib and anti PD-1/L1	sotorasib	Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
Phase 1 combination arm with sotorasib and anti PD-1/L1	Anti PD-1/L1	Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
Phase 1 monotherapy treatment naive advanced NSCLC	sotorasib	Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
Phase 1 monotherapy treatment naive advanced NSCLC	Midazolam	Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
Phase 2 monotherapy dose comparison	sotorasib	Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy
Phase 1 Does escalation and Expansion monotherapy BID	sotorasib	BID 2L+solid tumors (fed state)

Primary Outcome Measures

Name	Time	Method
Primary: Number of subjects with adverse events of interest	24 Months	Adverse events of interest will be a primary outcome measure in the following group: - Phase 2 monotherapy dose comparison
Primary: Number of subjects with treatment-emergent adverse events	24 Months	Treatment-emergent adverse events will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC; * Phase 2 monotherapy dose comparison
Primary: Number of subjects with clinically significant changes in physical examination results	Baseline to 24 Months	Physical examinations will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1
Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)	Baseline to 24 Months	ECGs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Number of subjects with treatment-related adverse events	24 Months	Treatment-related adverse events will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Number of subjects with grade ≥3 treatment-emergent adverse events	24 Months	Grade ≥3 treatment-emergent adverse events will be a primary outcome measure in the following group: - Phase 2 monotherapy dose comparison
Primary: Number of subjects with serious adverse events	24 Months	Serious adverse events will be a primary outcome measure in the following group: - Phase 2 monotherapy dose comparison
Primary: Number of subjects with clinically significant changes in vital signs	Baseline to 24 Months	Vital signs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteria	24 Months	DOR will be a primary outcome measure in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Number of subjects with dose-limiting toxicities (DLTs)	21 Days	DLTs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Number of subjects with clinically significant changes in clinical laboratory values	Baseline to 24 Months	Abnormal clinical laboratory values will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria	24 Months	ORR will be a primary outcome measure in the following group: * Phase 1 monotherapy treatment naïve advanced NSCLC; * Phase 2 monotherapy; * Phase 2 monotherapy dose comparison
Primary: Disease control as assessed by RECIST 1.1 criteria	24 Months	Disease control will be a primary outcome measure in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria	24 Months	Duration of SD will be a primary outcome measure in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Primary: Time to response (TTR) as assessed by RECIST 1.1 criteria	24 Months	TTR will be a primary outcome measure in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC

Secondary Outcome Measures

Name	Time	Method
Secondary: Plasma concentration (Cmax) of sotorasib	15 Weeks	Cmax will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC; * Phase 2 monotherapy dose comparison
Secondary: Plasma concentration (Cmax) of midazolam	16 Days	Cmax of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: Time to achieve Cmax (Tmax) of sotorasib	15 Weeks	Tmax will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: Area under the plasma concentration-time curve (AUC) of sotorasib	15 Weeks	AUC will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 1 monotherapy treatment naïve advanced NSCLC; * Phase 2 monotherapy dose comparison
Secondary: Area under the plasma concentration-time curve (AUC) of midazolam	16 Days	AUC of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: Clearance of midazolam from the plasma	16 Days	Clearance of midazolam from the plasma will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: Terminal half-life (t1/2) of midazolam	16 Days	t1/2 of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: - Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria	24 Months	ORR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1
Secondary: Duration of response (DOR) as assessed by RECIST 1.1 criteria	24 Months	DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 2 monotherapy dose comparison
Secondary: Disease control as assessed by RECIST 1.1 criteria	24 Months	DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 2 monotherapy dose comparison
Secondary: Progression-free survival (PFS) as assessed by RECIST 1.1 criteria	24 Months	PFS will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 2 monotherapy dose comparison; * Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria	24 Months	Duration of SD will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1
Secondary: Depth of response (best percentage change from baseline in lesion sum diameters) as assessed by RECIST 1.1 criteria	Baseline to 24 Months	Depth of response will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Time to response (TTR) as assessed by RECIST 1.1 criteria	24 Months	DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 2 monotherapy dose comparison
Secondary: Overall survival (OS)	24 Months	OS will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy; * Phase 2 monotherapy; * Phase 1 combination arm with sotorasib and anti PD-1/L1; * Phase 2 monotherapy dose comparison; * Phase 1 monotherapy treatment naïve advanced NSCLC
Secondary: sotorasib exposure and QTc interval relationship	24 Months	sotorasib exposure and QTc interval relationship will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy; * Phase 1 Dose Expansion Part 2 monotherapy
Secondary: Progression-free survival (PFS) at 6 months	6 Months	PFS at 6 months will be a secondary outcome measure for the following group: - Phase 2 monotherapy
Secondary: Progression-free survival (PFS) at 12 months	12 Months	PFS at 12 months will be a secondary outcome measure for the following group: - Phase 2 monotherapy
Secondary: Overall survival (OS) at 12 months	12 Months	OS at 12 months will be a secondary outcome measure for the following group: - Phase 2 monotherapy
Secondary: Number of subjects with treatment-emergent adverse events	24 Months	Treatment-emergent adverse events will be a secondary outcome measure for the following group: - Phase 2 monotherapy
Secondary: Number of subjects with grade ≥3 treatment-emergent adverse events	24 Months	Grade ≥3 treatment-emergent adverse events will be a secondary outcome measure for the following group: - Phase 2 monotherapy
Secondary: Impact of treatment on disease-related symptoms and health related quality of life (HRQOL) as assessed by EORTC QLQ-C30	24 Months	Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by disease-specific modules Quality-of-Life Questionnaire Lung Cancer Module (QLQ LC13)	24 Months	Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by non-small cell lung cancer symptom assessment questionnaire (NSCLC SAQ) for NSCLC	24 Months	Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Severity (PGIS)	24 Months	Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Change (PGIC) in cough, dyspnea and chest pain for NSCLC	24 Months	Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Treatment-related symptoms and impact on the subject as assessed by EORTC QLQ-C30	24 Months	Treament related symptoms and impact on the subject will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Treatment-related symptoms and impact on the subject as assessed by selected questions from the Patient-reported Outcome of the Common Terminology Criteria for Adverse Events (PRO-CTCAE library)	24 Months	Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Treatment-related symptoms and impact on the subject as assessed by a single item about symptom bother, item GP5 of the Functional Assessment of Cancer Therapy - General (FACT-G)	24 Months	Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison
Secondary: Change from baseline in physical function as assessed by EORTC QLQ-C30	Baseline to 24 Months	Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: - Phase 2 monotherapy dose comparison

Trial Locations

Locations (133)

Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Gibbs Cancer Center and Research Institute - Spartanburg; 🇺🇸 Spartanburg, South Carolina, United States

US Oncology Research Investigational Products Center; 🇺🇸 Fairfax, Virginia, United States

Dana Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz; 🇭🇺 Szekesfehervar, Hungary

Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca; 🇷🇴 Cluj Napoca, Romania

Spitalul Municipal Ploiesti; 🇷🇴 Ploiesti, Romania

Centro Hospitalar Universitario do Porto EPE - Hospital de Santo Antonio; 🇵🇹 Porto, Portugal

Universitaetsspital Basel; 🇨🇭 Basel, Switzerland

Szent Borbala Korhaz; 🇭🇺 Tatabanya, Hungary

Washington University; 🇺🇸 Saint Louis, Missouri, United States

City of Hope National Medical Center; 🇺🇸 Duarte, California, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Universitaetsklinikum Allgemeines Krankenhaus Wien; 🇦🇹 Wien, Austria

Institut Jules Bordet; 🇧🇪 Brussels, Belgium

Ziekenhuis Oost-Limburg; 🇧🇪 Genk, Belgium

AZ Delta Campus Rumbeke; 🇧🇪 Roeselare, Belgium

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

University of Pittsburgh Medical Center Cancer Pavillion; 🇺🇸 Pittsburgh, Pennsylvania, United States

University of Texas Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States

Virginia Cancer Specialists PC; 🇺🇸 Fairfax, Virginia, United States

Scientia Clinical Research Ltd; 🇦🇺 Randwick, New South Wales, Australia

Laura and Isaac Perlmutter Cancer Center at New York University Langone; 🇺🇸 New York, New York, United States

Texas Oncology - Baylor; 🇺🇸 Dallas, Texas, United States

Grand Hopital de Charleroi; 🇧🇪 Charleroi, Belgium

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

University of Florida Health; 🇺🇸 Gainesville, Florida, United States

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

Irmandade da Santa Casa de Misericordia de Porto Alegre, Nucleo de Novos Tratamentos em Cancer; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

The Ottawa Hospital Cancer Centre; 🇨🇦 Ottawa, Ontario, Canada

Medizinische Universitaet Innsbruck; 🇦🇹 Innsbruck, Austria

Krankenhaus Nord - Klinik Floridsdorf; 🇦🇹 Wien, Austria

Somogy Megyei Kaposi Mor Oktato Korhaz; 🇭🇺 Kaposvar, Hungary

Institut Bergonie; 🇫🇷 Bordeaux, France

Blue Ridge Cancer Care; 🇺🇸 Salem, Virginia, United States

Semmelweis Egyetem; 🇭🇺 Budapest, Hungary

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center; 🇯🇵 Yokohama-shi, Kanagawa, Japan

Seattle Cancer Care Alliance; 🇺🇸 Seattle, Washington, United States

Tom Baker Cancer Centre; 🇨🇦 Calgary, Alberta, Canada

Universitair Ziekenhuis Antwerpen; 🇧🇪 Edegem, Belgium

Universitair Ziekenhuis Leuven - Campus Gasthuisberg; 🇧🇪 Leuven, Belgium

London Regional Cancer Program, London Health Sciences Centre; 🇨🇦 London, Ontario, Canada

Sociedade Beneficente de Senhoras Hospital Sirio Libanes; 🇧🇷 Sao Paulo, São Paulo, Brazil

Instituto Coi; 🇧🇷 Rio de Janeiro, Brazil

Centre Hospitalier Intercommunal de Créteil; 🇫🇷 Créteil, France

Universitaetsklinikum Krems; 🇦🇹 Krems, Austria

Universitair Ziekenhuis Gent; 🇧🇪 Gent, Belgium

Centre Hospitalier Universitaire de Liege; 🇧🇪 Liege, Belgium

Universitatsklinikum Koln; 🇩🇪 Köln, Germany

National Cancer Center Hospital East; 🇯🇵 Kashiwa-shi, Chiba, Japan

Klinikum der Universität München Campus Grosshadern; 🇩🇪 München, Germany

Aichi Cancer Center; 🇯🇵 Nagoya-shi, Aichi, Japan

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Institutul Oncologic, Prof Dr Alexandru Trestioreanu; 🇷🇴 Bucuresti, Romania

Hospital Universitari Germans Trias i Pujol; 🇪🇸 Badalona, Cataluña, Spain

Hospital General Universitario Gregorio Marañon; 🇪🇸 Madrid, Spain

Fundacion Jimenez Diaz; 🇪🇸 Madrid, Spain

The Cancer Institute Hospital of Japanese Foundation for Cancer Research; 🇯🇵 Koto-ku, Tokyo, Japan

Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano; 🇵🇹 Matosinhos, Portugal

Wakayama Medical University Hospital; 🇯🇵 Wakayama-shi, Wakayama, Japan

Severance Hospital Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea Seoul St Marys Hospital; 🇰🇷 Seoul, Korea, Republic of

Centro Hospitalar Universitario de Lisboa Norte EPE - Hospital Pulido Valente; 🇵🇹 Lisboa, Portugal

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Kansai Medical University Hospital; 🇯🇵 Hirakata-shi, Osaka, Japan

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of

National Cancer Center; 🇰🇷 Goyang-si Gyeonggi-do, Korea, Republic of

Osaka International Cancer Institute; 🇯🇵 Osaka-shi, Osaka, Japan

Hospital Cuf porto; 🇵🇹 Porto, Portugal

Institutul Regional de Oncologie Iasi; 🇷🇴 Iasi, Romania

Universitaetsspital Zuerich; 🇨🇭 Zurich, Switzerland

Hospital Universitario Madrid Sanchinarro; 🇪🇸 Madrid, Spain

Henry Dunant Hospital Center; 🇬🇷 Athens, Greece

Metropolitan Hospital; 🇬🇷 Athens, Greece

University Hospital of Heraklion; 🇬🇷 Heraklion - Crete, Greece

Theagenion Cancer Hospital; 🇬🇷 Thessaloniki, Greece

Agios Loukas Clinic; 🇬🇷 Thessaloniki, Greece

Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Henry Ford Health System; 🇺🇸 Detroit, Michigan, United States

University of California at SF; 🇺🇸 San Francisco, California, United States

Rocky Mountain Cancer Centers; 🇺🇸 Denver, Colorado, United States

Sarah Cannon Research Institute at HealthONE; 🇺🇸 Denver, Colorado, United States

Vanderbilt University Ingram Cancer Center; 🇺🇸 Nashville, Tennessee, United States

Huntsman Cancer Institute; 🇺🇸 Salt Lake City, Utah, United States

Moffitt Cancer Center; 🇺🇸 Tampa, Florida, United States

American Oncology Partners of Maryland, PA; 🇺🇸 Bethesda, Maryland, United States

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Medical Oncology Hematology Consultants Helen F Graham Cancer Center; 🇺🇸 Newark, Delaware, United States

University of California Los Angeles; 🇺🇸 Los Angeles, California, United States

Sarcoma Oncology Research Center LLC; 🇺🇸 Santa Monica, California, United States

Indiana University; 🇺🇸 Indianapolis, Indiana, United States

Duke University Medical Center, Morris Cancer Clinic; 🇺🇸 Durham, North Carolina, United States

Fox Chase Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

The Queen Elizabeth Hospital; 🇦🇺 Woodville South, South Australia, Australia

Princess Alexandra Hospital; 🇦🇺 Woolloongabba, Queensland, Australia

Peter MacCallum Cancer Centre; 🇦🇺 Parkville, Victoria, Australia

Medizinische Universitaet Graz; 🇦🇹 Graz, Austria

Jessa Ziekenhuis - Campus Virga Jesse; 🇧🇪 Hasselt, Belgium

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada

McGill University Health Centre Glen Site; 🇨🇦 Montreal, Quebec, Canada

Gustave Roussy; 🇫🇷 Villejuif, France

Hopital de la Timone; 🇫🇷 Marseille cedex 5, France

Institut Claudius Regaud; 🇫🇷 Toulouse cedex 9, France

Institut Curie; 🇫🇷 Paris, France

Universitätsklinikum Essen; 🇩🇪 Essen, Germany

Tudogyogyintezet Torokbalint; 🇭🇺 Torokbalint, Hungary

National Hospital Organization Shikoku Cancer Center; 🇯🇵 Matsuyama-shi, Ehime, Japan

Sendai Kousei Hospital; 🇯🇵 Sendai-shi, Miyagi, Japan

National Hospital Organization Kyushu Cancer Center; 🇯🇵 Fukuoka-shi, Fukuoka, Japan

Niigata Cancer Center Hospital; 🇯🇵 Niigata-shi, Niigata, Japan

National Hospital Organization Hokkaido Cancer Center; 🇯🇵 Sapporo-shi, Hokkaido, Japan

St Marianna University Hospital; 🇯🇵 Kawasaki-shi, Kanagawa, Japan

Okayama University Hospital; 🇯🇵 Okayama-shi, Okayama, Japan

Shizuoka Cancer Center; 🇯🇵 Sunto-gun, Shizuoka, Japan

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Clinica Universidad de Navarra; 🇪🇸 Madrid, Spain

Hospital General Universitario de Valencia; 🇪🇸 Valencia, Comunidad Valenciana, Spain

Texas Oncology - Austin Central; 🇺🇸 Austin, Texas, United States

Centrul de Radioterapie Amethyst Cluj; 🇷🇴 Cluj Napoca, Romania

Centrul de Oncologie Sf Nectarie SRL; 🇷🇴 Craiova, Romania

SC Oncomed SRL; 🇷🇴 Timisoara, Romania

Hospital de Base de Sao Jose do Rio Preto; 🇧🇷 São José do Rio Preto, São Paulo, Brazil

Oncologia Rede D´Or; 🇧🇷 Sao Paulo, São Paulo, Brazil

Hopitaux Universitaires de Geneve; 🇨🇭 Geneve, Switzerland

University Hospitals Cleveland Medical Center; 🇺🇸 Cleveland, Ohio, United States

Orszagos Koranyi Pulmonologiai Intezet; 🇭🇺 Budapest, Hungary

Fundacao Champalimaud; 🇵🇹 Lisboa, Portugal

SC Medisprof SRL; 🇷🇴 Cluj Napoca, Romania

Smilow Cancer Hospital at Yale New Haven; 🇺🇸 New Haven, Connecticut, United States

AdventHealth Orlando Infusion Center; 🇺🇸 Orlando, Florida, United States